volume 22 issue 2 pages 112-123

Natural killer cells in antiviral immunity

Publication typeJournal Article
Publication date2021-06-11
scimago Q1
wos Q1
SJR17.458
CiteScore84.7
Impact factor60.9
ISSN14741733, 14741741
Energy Engineering and Power Technology
Fuel Technology
Abstract
Natural killer (NK) cells play an important role in innate immune responses to viral infections. Here, we review recent insights into the role of NK cells in viral infections, with particular emphasis on human studies. We first discuss NK cells in the context of acute viral infections, with flavivirus and influenza virus infections as examples. Questions related to activation of NK cells, homing to infected tissues and the role of tissue-resident NK cells in acute viral infections are also addressed. Next, we discuss NK cells in the context of chronic viral infections with hepatitis C virus and HIV-1. Also covered is the role of adaptive-like NK cell expansions as well as the appearance of CD56− NK cells in the course of chronic infection. Specific emphasis is then placed in viral infections in patients with primary immunodeficiencies affecting NK cells. Not least, studies in this area have revealed an important role for NK cells in controlling several herpesvirus infections. Finally, we address new data with respect to the activation of NK cells and NK cell function in humans infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) giving rise to coronavirus disease 2019 (COVID-19). This Review covers the role of natural killer cells in acute and chronic viral infections, with emphasis on human infections and insights from patients with primary immunodeficiencies affecting natural killer cells. It also describes the emerging data on how natural killer cells are involved in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Found 
Found 

Top-30

Journals

5
10
15
20
25
30
35
40
45
Frontiers in Immunology
41 publications, 10.88%
Nature Communications
7 publications, 1.86%
Nature Immunology
6 publications, 1.59%
Viruses
5 publications, 1.33%
International Journal of Molecular Sciences
5 publications, 1.33%
Current Opinion in HIV and AIDS
4 publications, 1.06%
Signal Transduction and Targeted Therapy
4 publications, 1.06%
eLife
4 publications, 1.06%
bioRxiv
4 publications, 1.06%
European Journal of Immunology
4 publications, 1.06%
iScience
4 publications, 1.06%
Biomedicines
3 publications, 0.8%
Frontiers in Cellular and Infection Microbiology
3 publications, 0.8%
Cell Reports
3 publications, 0.8%
Cell Reports Medicine
3 publications, 0.8%
EBioMedicine
3 publications, 0.8%
Journal for ImmunoTherapy of Cancer
3 publications, 0.8%
Pathogens
3 publications, 0.8%
Diagnostics
3 publications, 0.8%
Journal of Medical Virology
3 publications, 0.8%
PLoS Pathogens
3 publications, 0.8%
Journal of Immunology
3 publications, 0.8%
Frontiers in Pharmacology
2 publications, 0.53%
Molecular Medicine
2 publications, 0.53%
Molecular Cancer
2 publications, 0.53%
International Immunopharmacology
2 publications, 0.53%
Current Opinion in Immunology
2 publications, 0.53%
Journal of Inflammation Research
2 publications, 0.53%
Journal of Infectious Diseases
2 publications, 0.53%
5
10
15
20
25
30
35
40
45

Publishers

10
20
30
40
50
60
70
80
Elsevier
73 publications, 19.36%
Springer Nature
67 publications, 17.77%
Frontiers Media S.A.
49 publications, 13%
MDPI
36 publications, 9.55%
Wiley
35 publications, 9.28%
Cold Spring Harbor Laboratory
23 publications, 6.1%
Ovid Technologies (Wolters Kluwer Health)
14 publications, 3.71%
Taylor & Francis
11 publications, 2.92%
Oxford University Press
7 publications, 1.86%
eLife Sciences Publications
4 publications, 1.06%
Public Library of Science (PLoS)
4 publications, 1.06%
BMJ
3 publications, 0.8%
American Chemical Society (ACS)
3 publications, 0.8%
American Society for Microbiology
3 publications, 0.8%
SAGE
3 publications, 0.8%
American Society for Clinical Investigation
2 publications, 0.53%
Mary Ann Liebert
2 publications, 0.53%
Proceedings of the National Academy of Sciences (PNAS)
2 publications, 0.53%
American Association for the Advancement of Science (AAAS)
2 publications, 0.53%
Baishideng Publishing Group
2 publications, 0.53%
American Society of Hematology
2 publications, 0.53%
SPb RAACI
2 publications, 0.53%
Begell House
1 publication, 0.27%
Korean Society of Food Science and Technology
1 publication, 0.27%
IOP Publishing
1 publication, 0.27%
Portland Press
1 publication, 0.27%
AIP Publishing
1 publication, 0.27%
Publishing House ABV Press
1 publication, 0.27%
10
20
30
40
50
60
70
80
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
377
Share
Cite this
GOST |
Cite this
GOST Copy
Björkström N. K., Strunz B., LJUNGGREN H. Natural killer cells in antiviral immunity // Nature Reviews Immunology. 2021. Vol. 22. No. 2. pp. 112-123.
GOST all authors (up to 50) Copy
Björkström N. K., Strunz B., LJUNGGREN H. Natural killer cells in antiviral immunity // Nature Reviews Immunology. 2021. Vol. 22. No. 2. pp. 112-123.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1038/s41577-021-00558-3
UR - https://doi.org/10.1038/s41577-021-00558-3
TI - Natural killer cells in antiviral immunity
T2 - Nature Reviews Immunology
AU - Björkström, Niklas K.
AU - Strunz, Benedikt
AU - LJUNGGREN, HANS-GUSTAF
PY - 2021
DA - 2021/06/11
PB - Springer Nature
SP - 112-123
IS - 2
VL - 22
PMID - 34117484
SN - 1474-1733
SN - 1474-1741
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2021_Björkström,
author = {Niklas K. Björkström and Benedikt Strunz and HANS-GUSTAF LJUNGGREN},
title = {Natural killer cells in antiviral immunity},
journal = {Nature Reviews Immunology},
year = {2021},
volume = {22},
publisher = {Springer Nature},
month = {jun},
url = {https://doi.org/10.1038/s41577-021-00558-3},
number = {2},
pages = {112--123},
doi = {10.1038/s41577-021-00558-3}
}
MLA
Cite this
MLA Copy
Björkström, Niklas K., et al. “Natural killer cells in antiviral immunity.” Nature Reviews Immunology, vol. 22, no. 2, Jun. 2021, pp. 112-123. https://doi.org/10.1038/s41577-021-00558-3.